Personalized Alpha-1 Antitrypsin Therapy for Reducing Acute Graft Versus Host Disease Risk

The invention provides an improved method for reducing the risk of acute graft versus host disease (aGVHD) in patients undergoing hematopoietic cell transplantation (HCT) by leveraging genetic profiling, personalized treatment schedules, and optimized alpha-1 antitrypsin (A1AT) dosing.

The original patent disclosed methods for reducing aGVHD risk by administering A1AT prior to and following HCT. However, these methods have limitations, including a one-size-fits-all approach to dosing and a lack of consideration for individual genetic profiles. The new inventive concept addresses these limitations by incorporating genetic profiling and personalized treatment schedules to minimize aGVHD risk.

The new inventive concept comprises a system and method for reducing aGVHD risk by administering A1AT according to a personalized treatment schedule based on the patient's genetic profile. The system includes a processor configured to analyze the patient's genetic data and determine the optimal A1AT dosage and administration schedule. The method involves monitoring the patient's cytokine levels and adjusting the A1AT dosage accordingly. Additionally, the inventive concept includes a composition for treating aGVHD, comprising A1AT and at least one immunomodulatory agent, administered in a single dose prior to HCT. A real-time monitoring system is also disclosed, comprising a sensor configured to detect biomarkers of aGVHD and a processor configured to adjust the A1AT dosage based on the detected biomarkers.

The new inventive concept provides a novel approach to aGVHD risk reduction by incorporating genetic profiling and personalized treatment schedules, which is not disclosed in the original patent. The use of genetic profiling to determine optimal A1AT dosing and administration schedules is a non-obvious improvement over the original patent.

Alternative embodiments of the inventive concept include using different types of genetic profiling, such as whole-genome sequencing or gene expression analysis, to determine optimal A1AT dosing. Additionally, the inventive concept could be adapted for use in other types of transplantation, such as solid organ transplantation.

The inventive concept has significant commercial potential in the field of hematopoietic cell transplantation, where aGVHD is a major complication. The market for aGVHD prevention and treatment is expected to grow significantly in the coming years, and the inventive concept is well-positioned to capitalize on this trend.